Eloralintide Phase 2 Results: 48-Week Trial

What did the eloralintide phase 2 trial find? In a 48-week randomized trial published in The Lancet, adults with obesity or overweight who received eloralintide lost between about 9% and 20% of body weight on average, depending on the study group, compared with 0.4% on placebo. Nausea and fatigue were the most common side effects. Eloralintide remains an investigational compound that no regulator has approved.

This original FirstLabs editorial review was updated November 3, 2026. It is educational information, not medical advice, a dosing guide or a recommendation for personal use. FirstLabs catalogue materials are for laboratory research only, not human or veterinary use.

How the trial was designed

Billings and colleagues enrolled 263 adults at 46 U.S. research centres. Participants were 18 to 75 years old and had a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. People with type 2 diabetes were excluded.

Participants were randomized to placebo or one of six eloralintide groups, some with fixed amounts and some with stepwise escalation, given once weekly for 48 weeks. The primary endpoint was percentage change in body weight. Average baseline weight was 109.1 kg and BMI 39.1; 78% of participants were women.

Body-weight results at 48 weeks

Using the trial's efficacy estimand, mean body-weight change across the eloralintide groups ranged from −9% in the lowest-exposure group to −20% in the highest groups. The placebo group changed by −0.4%. The effect was dose-dependent.

An efficacy estimand estimates results as if participants stayed on treatment as intended. It can be larger than a treatment-regimen estimate that counts everyone regardless of discontinuation. Compare like with like when reading headline percentages.

Side effects reported

Nausea was the most common adverse event. Rates varied widely by group, from 11% to 64%, compared with 14% on placebo. Fatigue ranged from 0% to 46% across eloralintide groups, compared with 12% on placebo. Groups using gradual escalation did not uniformly have lower rates.

The authors described the drug as generally well tolerated. A 48-week trial with 263 participants cannot establish long-term safety or rare adverse effects.

How to compare it with other obesity research

Eloralintide acts at amylin receptors, not at GLP-1 or GIP receptors like tirzepatide. Results from different trials involve different populations, durations and estimands, so they cannot be ranked by placing percentages side by side. The trial was funded by Eli Lilly, and several authors are company employees.

Phase 3 trials are needed before any regulator can assess eloralintide for approval. No Health Canada authorization exists.

Eloralintide phase 2: frequently asked questions

How much weight was lost in the eloralintide trial?

Average losses ranged from about 9% to 20% across study groups over 48 weeks, compared with 0.4% with placebo.

Is eloralintide approved in Canada?

No. It is investigational and has no Health Canada authorization.

Do these results apply to research vials?

No. Trial results belong to the studied formulation and population. FirstLabs material is for laboratory research only.

Laboratory documentation is a separate question

Evidence about eloralintide in a clinical study does not establish that a FirstLabs vial is equivalent to the studied formulation. A certificate of analysis describes the submitted sample, not medical suitability or regulatory authorization. HPLC purity does not by itself establish quantity, sterility, endotoxin control or a match to current stock.

For laboratory records, verify exact identity and labelled size, analytical methods, measured quantity, sample identifiers and any available lot-to-stock documentation. A laboratory task ID is not automatically a manufacturing lot. Keep missing reports and adverse results visible rather than borrowing evidence from another size.

Related reading: Eloralintide receptor selectivity, early development and phase 1 studies and the Eloralintide Canada guide. The Eloralintide 10mg catalogue entry is a laboratory quantity, not a clinical dose. The cover is an illustrative scene, not trial data.

Read our COA verification checklist, published laboratory reports and Canadian regulation overview for these distinctions.

Primary sources and editorial scope

FirstLabs is a research-material supplier with a commercial interest in the compounds discussed, not a licensed pharmacy or an independent medical authority. Results belong to their original study populations, formulations and endpoints. No personal outcome, treatment protocol or authorization of catalogue products is implied.

Eloralintide Phase 2 Trial Results: 48-Week Lancet Study Explained